@article{26c1e3fc992f464b9f55db5f1c715b0b,
title = "Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer",
keywords = "METRONOMIC CHEMOTHERAPY, 1ST-LINE TREATMENT, CLINICAL-OUTCOMES, TREATMENT PATTERNS, OPEN-LABEL, CYCLOPHOSPHAMIDE, CAPECITABINE, BENEFIT, BEVACIZUMAB, SURVIVAL",
author = "Claessens, {Anouk K. M.} and Erdkamp, {Frans L. G.} and Marta Lopez-Yurda and Bouma, {Jeanette M.} and Rademaker-Lakhai, {Jeany M.} and Honkoop, {Aafke H.} and {de Graaf}, Hiltje and Tjan-Heijnen, {Vivianne C. G.} and Bos, {Monique E. M. M.} and {Dutch Breast Canc Res Grp BOOG}",
year = "2020",
month = jun,
day = "2",
doi = "10.1080/0284186X.2020.1731923",
language = "English",
volume = "59",
pages = "713--722",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Routledge/Taylor & Francis Group",
number = "6",
}